Top-line results expected H1 2022
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan.
… ProQR to Present Findings from Phase 1/2 Interim Analysis of … & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … page on the Investors section of the Company’s website, www.ProQR.com . The dial-in details for the call are +1 …
… ProQR Announces Publication in Nature Medicine of QR-110 Data … and CAMBRIDGE, Mass., Dec. 17, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … is expected to start in the first half of 2019. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Receives Fast Track Designation from FDA for QR-1123 … Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We look forward to beginning enrollment in the Phase …